# Primary Central Nervous System Lymphoma With Testicular and Prostatic Involvement: A Case Report

**Authors:** Javier A Rodríguez Morales, Valeria Murguía Salgado, Valdemar Barajas López, Alejandra Alvarez Salinas, Lauro F Amador

PMC · DOI: 10.7759/cureus.101783 · Cureus · 2026-01-18

## TL;DR

A rare case of brain lymphoma in an otherwise healthy man also involved the testicles and prostate, requiring aggressive treatment.

## Contribution

Reports a rare case of primary CNS DLBCL with unusual early testicular and prostatic involvement in an immunocompetent patient.

## Key findings

- Primary CNS DLBCL presented with testicular and prostatic involvement in an immunocompetent individual.
- PET-CT identified secondary extranodal disease in the testes and prostate.
- Treatment with high-dose methotrexate-based chemotherapy was initiated following guidelines.

## Abstract

Diffuse large B-cell lymphoma (DLBCL) is an aggressive subtype of non-Hodgkin lymphoma that most commonly presents with nodal disease, while primary involvement of the central nervous system (CNS) is rare, particularly in immunocompetent patients. We describe the case of a 41-year-old immunocompetent male who presented with progressive left-sided hemiparesis, ipsilateral facial palsy, severe headache, and decreased level of consciousness. Neuroimaging findings and histopathological examination confirmed the diagnosis of primary CNS DLBCL. Subsequent systemic evaluation with PET-CT revealed increased metabolic activity in the testicular and prostatic regions, consistent with secondary extranodal involvement. The patient was treated with a MATRIX-based chemotherapy regimen, including high-dose methotrexate, cytarabine, and rituximab, in accordance with current guidelines for primary CNS lymphoma. This case highlights an unusual presentation of primary CNS DLBCL with early systemic dissemination to testicular and prostatic tissue, underscoring the importance of comprehensive staging and prompt initiation of high-dose methotrexate-based therapy to optimize clinical outcomes.

## Linked entities

- **Chemicals:** methotrexate (PubChem CID 4112), cytarabine (PubChem CID 6253)
- **Diseases:** Diffuse large B-cell lymphoma (MONDO:0018905), non-Hodgkin lymphoma (MONDO:0018908), primary central nervous system lymphoma (MONDO:0002571)

## Full-text entities

- **Genes:** KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, IRF4 (interferon regulatory factor 4) [NCBI Gene 3662] {aka IMD131, LSIRF, MUM1, NF-EM5, SHEP8}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, PWWP3A (PWWP domain containing 3A, DNA repair factor) [NCBI Gene 84939] {aka EXPAND1, HSPC211, MUM-1, MUM1}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CD79B (CD79b molecule) [NCBI Gene 974] {aka AGM6, B29, IGB, Igbeta}, BCL6 (BCL6 transcription repressor) [NCBI Gene 604] {aka BCL5, BCL6A, LAZ3, ZBTB27, ZNF51}, PAX5 (paired box 5) [NCBI Gene 5079] {aka ALL3, BSAP, PAX-5}, MME (membrane metalloendopeptidase) [NCBI Gene 4311] {aka CALLA, CD10, CMT2T, NEP, SCA43, SFE}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}
- **Diseases:** anxiety (MESH:D001007), eye deviation (MESH:D010262), malignancy (MESH:D009369), neurotoxicity (MESH:D020258), polyuric syndrome (MESH:D013577), pain (MESH:D010146), headache (MESH:D006261), nodal disease (MESH:D004194), systemic disease (MESH:D034721), vomiting (MESH:D014839), frontoparietal lesion (MESH:C536673), motor deficits (MESH:D009461), paralysis (MESH:D010243), testicular cancer (MESH:D013736), lesion (MESH:D009059), vasogenic edema (MESH:D001929), hemiparesis (MESH:D010291), parietal lesion (MESH:C566826), hypermetabolic lesions (MESH:C565498), infectious complications (MESH:D003141), anisocoria (MESH:D015875), neurological deterioration (MESH:D009422), facial palsy (MESH:D005158), Coma (MESH:D003128), oncologic disorders (MESH:D000072716), CAP (OMIM:115650), hydrocele (MESH:D006848), DLBCL (MESH:D016403), tumor lysis syndrome (MESH:D015275), extranodal non-Hodgkin lymphoma (MESH:D008228), CNS lymphoma (MESH:D008223), intracranial hypertension (MESH:D019586)
- **Chemicals:** oxygen (MESH:D010100), blood glucose (MESH:D001786), thiotepa (MESH:D013852), methotrexate (MESH:D008727), 18F-fluorodeoxyglucose (MESH:D019788), rituximab (MESH:D000069283), hematoxylin (MESH:D006416), sodium (MESH:D012964), pCO2 (-), cytarabine (MESH:D003561)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12911529/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12911529/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC12911529/full.md

---
Source: https://tomesphere.com/paper/PMC12911529